Skip to main content

Table 1 Clinical characteristics of childhood acute leukaemia patients involved in discovery and validation cohorts

From: MicroRNA-181a as novel liquid biopsy marker of central nervous system involvement in pediatric acute lymphoblastic leukemia

Total number of examined samplesSamples
Discovery cohortValidation cohort
20138
Control group (sample type, number of individuals)PB, n = 10CSF, n = 6
IDDiagnosis, treatmentCSF cytology (CNS status according to protocol)CSFCSFBMPB
CNS+ patient group
 P1ALL, late-onset Relblymphoid cells with unambiguous blasts (CNS-2)d0d0, d15d0, d15, d30d0, d15, d30
 P2ALL, de novoc86 WBCs; high amount of blasts (CNS-3)d0, d15d0, d15, d32, d45d37d0, d37
 P3ALL, de novoa1 unambiguous blast, 2 suspicious cells (CNS-2)d0d0, d15, d33d0, d15, d33d0, d15, d33
 P4ALL, de novoa4 WBCs/μl with blasts (CNS-2)d0, d15
 P5ALL, de novoa18 lymphoid cells (mainly blasts), 20 Gumprecht shadows (CNS-2)d0, d15d0, d15d0, d15
 P6ALL, de novoa1 unambiguous blast (CNS-2)d0, d15, d33d0, d15, d33d0, d15, d33
 P7MPAL, de novoasome cells, 70% blast (CNS-2)d15, d33d0, d15, d33d0, d15, d33
 P8AML, de novod53 cells; 8% blast (CNS-2)d0, d15d0d0, d15
 P9AML, de novod7 WBCs/μl; numerous blasts (CNS-3)d0, d28d0, d28d0, d28
 P10ALL, early-onset Relb43 WBCs, mostly blasts (CNS-3)d0d0
 P11ALL, de novoanucleated cells, 70% blast (CNS-2)d0, d15
 P12ALL, de novoa35 lymphoid cells with 10% blast (CNS-2)d0, d15, d26, d40
CNS patient group
 P13ALL, de novoa1 cell/μl without blasts (CNS-1)d0
 P14ALL, de novoawithout cells (CNS-1)d0
 P15ALL, de novoawithout cells (CNS-1)d0
 P16ALL, de novoa1 cell/μl without blasts (CNS-1)d0
 P17ALL, early-onset Relbsquamous cells, 2 lymphocyte, 1 Gumprecht shadow (CNS-1)d0, d15d0, d15, d37d0, d15, d37
 P18ALL, early-onset Relbwithout cells (CNS-1)d0, d15d0, d15d0, d15
 P19ALL, de novoawithout cells (CNS-1)d0, d15, d33d0, d15, d33d0, d15, d33
 P20ALL, de novoaonly a few RBCs (CNS-1)d0, d15d0, d15, d33d0, d15, d33
 P21ALL, de novoa2 cells without blasts (CNS-1)d0, d15, d33d0, d15, d33d0, d15, d33
 P22MPAL, de novoaa few squamous cells on cytospin (CNS-1)d15, d38d0, d15, d38d0, d15, d38
 P23AML, de novodsome RBCs without blasts (CNS-1)d0d0, d23d0, d15, d23
 P24AML, de novod1 segmented, 2 band neutrophil granulocytes (CNS-1)d0, d28d0, d15, d28d28
 P25ALL, de novoa1 segment, 8 WBC (CNS-1)d0d0
 P26ALL, de novoawithout cells (CNS-1)d0
 P27ALL, de novoawithout cells (CNS-1)d0
 P28ALL, de novoa4 segmented neutrophil cells, 3 lymphocytes, 1 monocyte, 1 Gumprecht shadow, but no blasts (CNS-1)d0
 P29ALL, de novoawithout cells (CNS-1)d0
  1. Treatment guidelines: aALL IC BFM 2009, bALL REZ BFM 2002, cInterfant 2006, dAML BFM 98
  2. CNS central nervous system, ALL acute lymphoblastic leukaemia, AML acute myeloid leukaemia, MPAL mixed phenotype acute leukaemia, Rel relapse, CSF cerebrospinal fluid, BM bone marrow, PB peripheral blood, WBC white blood cell, RBC red blood cell, d day